EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 759 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Proof of Concept for the Safety and Immunogenicity of Lymph Node... January 18, 2024 Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab May 5, 2023 FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease August 18, 2021 Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer August 9, 2019 Load more HOT NEWS A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... New study supports extending cervical screening intervals for people who test... Boy Born With Heart Defect Gets Surgery To Help It Triple... Reflections from our chief clinician: The essential role of our research...
